Martin Auster - 05 Sep 2023 Form 4 Insider Report for Ventyx Biosciences, Inc. (VTYX)

Role
Chief Financial Officer
Signature
/s/ Christopher Krueger, as Attorney-in-Fact
Issuer symbol
VTYX
Transactions as of
05 Sep 2023
Net transactions value
-$863,334
Form type
4
Filing time
07 Sep 2023, 16:31:22 UTC
Previous filing
26 Jul 2023
Next filing
19 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VTYX Common Stock Sale $591,183 -18,327 -38% $32.26 29,322 05 Sep 2023 Direct F1, F2
transaction VTYX Common Stock Sale $272,049 -8,142 -28% $33.41 21,180 05 Sep 2023 Direct F1, F3
transaction VTYX Common Stock Sale $102 -3 -0.01% $33.98 21,177 05 Sep 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2022.
F2 Represents the weighted average share price of an aggregate total of 18,327 shares sold in the price range of $31.97 to $32.8321. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Represents the weighted average share price of an aggregate total of 8,142 shares sold in the price range of $32.97 to $33.96. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.